Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CYAD-101 · 1 trial · 1 indication
The occurrence of DLT during the 'DLT reporting period' is defined as the period from study enrollment on D1 (Visit 1) up to 3 weeks after first pembrolizumab treatment on D73 (Visit 14).
The objective response rate (ORR) at the tumor assessment on Day 94 \[Visit 15\]), 6 weeks after the first pembrolizumab treatment administration.
| Arm | Type | Description |
|---|---|---|
| CYAD-101 with FOLFOX Infusion administered concurrently followed by pembrolizumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CYAD-101 | DRUG | Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells |
| FOLFOX | DRUG | 5-FU, leucovorin and oxaliplatin |
| Pembrolizumab | DRUG | Humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) |
Key Inclusion Criteria: 1. Histologically proven metastatic adenocarcinoma of the colon or rectum. 1. Confirmed metastatic unresectable adenocarcinoma of the colon or the rectum. 2. Confirmed non-microsatellite instability high (non-MSI-H)/mismatch-repair proficient (pMMR) tumor status 3....
CYAD-101 is being studied for the treatment of unresectable metastatic colorectal cancer. It is an investigational small molecule therapy currently in Phase 1 clinical development. The drug is being evaluated in combination with other treatments to assess its safety and efficacy in patients with this advanced form of colorectal cancer.
CYAD-101 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. Merck is conducting clinical trials to evaluate the safety and effectiveness of this investigational drug for the treatment of unresectable metastatic colorectal cancer.
CYAD-101 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The ongoing Phase 1 trial is recruiting participants to evaluate the drug's safety, tolerability, and preliminary efficacy in patients with unresectable metastatic colorectal cancer.
CYAD-101 is being studied in a Phase 1 clinical trial with the identifier NCT04991948. This trial is titled 'Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer' and is currently recruiting participants in the United States and Belgium. The trial aims to enroll 34 patients with unresectable metastatic colorectal cancer.
No, the ongoing clinical trial of CYAD-101 is not randomized and does not use a control group. It is an uncontrolled, open-label study, meaning all participants receive the investigational treatment. The trial is also not double-blinded, as both researchers and participants are aware of the treatment being administered.